Artificial Intelligence (AI) In Drug Discovery
Aug 01, 2024
Stryker’s Spine Guidance 5 Software FDA Approval; VIALASE Received CE Mark; The Texas Heart Institute Implanted the BiVACOR® Total Artificial Heart; Diamyd Medical’s Phase 3 Trial Positive Results; Cardio Diagnostics Holdings Inc.’s CDIO.AI; GE Healthcare and AWS Strategic Collaboration
FDA Approved Stryker’s Spine Guidance 5 Software Featuring Copilot On July 30, 2024, Stryker, a global leader in medical technologies, announced that its Q Guidance System with Spine Guidance 5 Software featuring Copilot received 510(k) clearance from the U.S. Food and Drug Administration. This first-to-market t...
Read More...
May 17, 2023
Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases
The role and application of Artificial Intelligence have grown at an immense pace in recent years. Globally, several companies including large & small scale businesses, education, retail, and telecommunications, among others are actively exploring opportunities to leverage the potential of AI in their organizat...
Read More...
Mar 15, 2023
Utilization of Artificial Intelligence for Drug Commercialization
The amount of health and "omics-related data" produced and stored has increased exponentially during the last few decades. In clinical trials, patient data can be gathered in real-time and examined using various artificial intelligence (AI) techniques; mobile devices can also be utilized to enhance certain facets o...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
